Armėnija - anglų - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

ebewe pharma ges. m.b.h. nfg. kg - doxorubicin (doxorubicin hydrochloride) - concentrate for solution for infusion - 2mg/ml

Armėnija - anglų - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

ebewe pharma ges. m.b.h. nfg. kg - doxorubicin (doxorubicin hydrochloride) - concentrate for solution for infusion - 2mg/ml

Airija - anglų - HPRA (Health Products Regulatory Authority)

seacross pharma (europe) limited - doxorubicin hydrochloride - concentrate for solution for infusion - 2 milligram(s)/millilitre - anthracyclines and related substances; doxorubicin

Airija - anglų - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - doxorubicin hydrochloride - concentrate for solution for infusion - 2 milligram(s)/millilitre - anthracyclines and related substances; doxorubicin

Izraelis - anglų - Ministry of Health

novartis israel ltd - doxorubicin hydrochloride - solution for injection/ concentrate for solution for infusion - doxorubicin hydrochloride 2 mg/ml - doxorubicin - doxorubicin - soft tissue and bone sarcomas, hodgkin's and non-hodgkin's lymphoma, acute lymphoblastic leukemia, acute myeloblastic leukemia, wilms` tumor, carcinomas of the thyroid, breast, ovary, bladder, small cell bronchogenic carcinoma and neuroblastoma.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium chloride - adriamycin has been used successfully to produce regression in neoplastic conditions such as: acute leukaemia, wilms' tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, lymphomas of both hodgkin's and non-hodgkin's type, bronchogenic (lung) carcinoma, thyroid carcinoma, hepatomas, ovarian carcinoma, etc. the main antitumour activities are listed in table 1 of the product information. adriamycin is also indicated by intravesical administration in the primary management of non-metastatic carcinoma of the bladder. (tis, t1, t2).

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

baxter healthcare corporation - doxorubicin hydrochloride (unii: 82f2g7bl4e) (doxorubicin - unii:80168379ag) - doxil liposomal infusion is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. doxil liposomal infusion is indicated for the treatment of aids-related kaposi's sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy. doxil liposomal infusion, in combination with bortezomib, is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy. doxil liposomal infusion is contraindicated in patients who have a history of severe hypersensitivity reactions, including anaphylaxis, to doxorubicin hydrochloride [see warnings and precautions (5.2)]. risk summary based on findings in animals and its mechanism of action, doxil liposomal infusion can cause fetal harm when administered to a pregnant woman; avoid the use of doxil liposomal infusion during the 1st trimester. in animal reproduction studies, doxil lip

Australija - anglų - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - doxorubicin (doxorubicin hydrochloride) has been used successfully both as a single agent and also in combination with other approved cancer chemotherapeutic agents to produce regression in neoplastic conditions such as acute lymphoblastic leukemia, acute myeloblastic leukemia, wilms? tumor, neuroblastomas, soft tissue sarcomas, bone sarcomas, breast carcinoma, gynecologic carcinomas, testicular carcinomas, bronchogenic carcinoma, hodgkin's disease, non-hodgkin's lymphoma, thyroid carcinoma, bladder carcinomas, squamous cell carcinoma of the head and neck, and gastric carcinoma

Australija - anglų - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; hydrochloric acid

Australija - anglų - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - adriamycin has been used successfully to produce regression in neoplastic conditions such as: acute leukaemia, wilms? tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, lymphomas of both hodgkin?s and non-hodgkin?s type, bronchogenic (lung) carcinoma, thyroid carcinoma, hepatomas, ovarian carcinoma, etc. adriamycin is also indicated by intravesical administration in the primary management of non-metastatic carcinoma of the bladder (tis, t1, t2).